PEOPLE - Organogenesis (US) makes promotion:
This article was originally published in Clinica
Tissue engineering company Organogenesis (Canton, Massachusetts) has promoted Steven Bernitz to the position of president and CEO. Mr Bernitz, who joined the company in 1999, replaces Michael Sabolinski, who will continue to serve as executive vice-president of medical and regulatory affairs and will replace Nancy Parenteau as chief scientific officer.
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
Discussions on the shape of health care have moved from “reimagining” to the next stage: building and executing on the vision. That is the thrust of EY’s NextWave Report: New Horizons 2019. Additionally, for medtechs seeking business continuum, “duality” is now a preoccupying thought.
The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.